New screening system for hepatitis C
February 10, 2010 by admin · Leave a Comment
Contact: Ryan Garcia
ryan.garcia99@tamu.edu
979-845-9237
Texas A&M University
A newly designed system of identifying molecules for treating hepatitis C should enable scientists to discover novel and effective therapies for the dangerous and difficult-to-cure disease of the liver, says Zhilei Chen, a Texas A&M University assistant professor of chemical engineering who helped develop the screening system.
Is hepatitis B virus genotype C independently associated with cirrhosis?
February 8, 2010 by admin · Leave a Comment
Contact: Ye-Ru Wang
wjg@wjgnet.com
86-105-908-0039
World Journal of Gastroenterology
Hepatitis B virus (HBV) genotypes have distinct geographical distributions, and have been shown to differ with regard to clinical outcome and prognosis. However, the relationship between HBV genotypes and liver cirrhosis remains controversial and no study on exploring the association between HBV genotypes and subclinical cirrhosis in community-based population has been reported.
Engineering a new way to study hepatitis C
January 24, 2010 by admin · Leave a Comment
Contact: Jennifer Hirsch
jfhirsch@mit.edu
617-253-1682
Massachusetts Institute of Technology Read more
Potential new class of drugs to combat hepatitis C identified by Stanford scientists
January 19, 2010 by admin · Leave a Comment
Contact: Bruce Goldman
goldmanb@stanford.edu
650-725-2106
Stanford University Medical Center
STANFORD, Calif. Stanford University School of Medicine scientists have discovered a novel class of compounds that, in experiments in vitro, inhibit replication of the virus responsible for hepatitis C. If these compounds prove effective in infected humans as well, they may dramatically accelerate efforts to confront this virus’s propensity to rapidly acquire drug resistance, while possibly skirting some of the troubling side effects common among therapies in current use and in late-stage development.
A novel and simple formula to predict treatment success in chronic hepatitis C
January 13, 2010 by admin · Leave a Comment
Contact: Lin Tian
wjg@wjgnet.com
0086-105-908-0039
World Journal of Gastroenterology
The likelihood of treatment success of 48 wk peg-interferon (PEG-IFN) plus ribavirin (RBV) therapy for chronic hepatitis C may be predicted by viral kinetics on therapy. In particular, recent studies have shown that sustained virological response (SVR) can be predicted by a rapid virological response (RVR), and an early virological response (EVR). Nevertheless, the current dosing regimens could potentially under-treat some patients and additional measurements of viral response is needed to facilitate individualization of therapy. Among predictive factors already reported, many are not readily available from daily clinical assessment, because they require genomic analyses and/or advanced experimental methods. The prediction with simply available data may be useful.
Head-to-head studies identify best treatment regimen for hep C
January 3, 2010 by admin · Leave a Comment
Contact: Alissa J. Cruz
media@gastro.org
301-272-1603
American Gastroenterological Association Read more
Natural compound blocks hepatitis C infection
January 3, 2010 by admin · Leave a Comment
Contact: Kim Irwin
kirwin@mednet.ucla.edu
310-206-2805
University of California - Los Angeles Read more
Blueberry leaves healing power for Hepatitis C
August 8, 2009 by admin · Leave a Comment
A chemical found in blueberry leaves has shown a strong effect in blocking the replication of the Hepatitis C virus, opening up a new avenue for treating chronic HCV infections, which affect 200 million people worldwide and can eventually lead to cirrhosis and liver cancer.
NEJM Study Points to New Era in Hepatitis C Treatment
June 4, 2009 by admin · Leave a Comment
HCV Protease Inhibitor Telaprevir Improves Response, Halves Treatment Time for Hepatitis C Patients
For patients with the most common form of hepatitis C, the addition of a hepatitis Cspecific protease inhibitor called telaprevir to the current standard therapy can significantly improve the chances of being cured, and it does it in half the time of standard therapy alone.
Advances being made in the treatment of hepatitis
June 2, 2009 by admin · Leave a Comment
Researchers are making great strides in the development of new treatments for hepatitis and in confirming the effectiveness of current treatments, according to several studies being presented at Digestive Disease Week 2009 (DDW).
